title: [Hormone therapy for breast cancer].
abstract: Breast cancer is a hormone responsive disease, and its proliferation and progression correlate with estrogen. Estrogen binds to estrogen receptor and induces various target genes, thus promoting proliferation of breast cancer cells. Therefore, the strategy of endocrine therapy is the blockade of estrogen action. We can use a luteinizing hormone releasing hormone agonist and aromatase inhibitor as an interruptor of supply, tamoxifen as an inhibitor of estrogen receptor, and medroxyprogesterone acetate with an anti-estrogen action. In this article, we review endocrine therapy for breast cancer patients based on recent clinical trials.
authors.affiliation: Cancer Chemotherapy Center University Hospital, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu 807-8555, Japan.
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Uramoto
authors.forename: Seiji
authors.initials: S
authors.lastname: Kagami
authors.forename: Atsushi
authors.initials: A
authors.lastname: Iwashige
authors.forename: Junichi
authors.initials: J
authors.lastname: Tsukada
mesh_terms: D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D006801:Humans; D008525:Medroxyprogesterone / Q000627:therapeutic use; D011300:Preoperative Care; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D047072:Aromatase Inhibitors; D004965:Estrogen Antagonists; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D007987:Gonadotropin-Releasing Hormone; D008525:Medroxyprogesterone